Feasibility for rare disease clinical trials is not just a preliminary check. It is a strategic driver that shapes trial outcomes. With small patient populations, strict inclusion criteria, and limited site expertise, feasibility must be grounded in reality from the start. In rare disease research, every early decision carries weight. Misjudging patient availability, site readiness, […]

Read More →

Executing an IIT is often more complex for various reasons, including the necessity for industry support. Therefore, conducting an early feasibility assessment/evaluation before commencing an IIT can help address most challenges. Investigator-initiated trials (IITs) are typically conducted at academic hospitals and universities, distinguishing them from regular clinical trials in several aspects. What are Investigator-Initiated Trials […]

Read More →